Clinical Trial Update: Activated Protein C to Treat Acute Lung Injuries [Phase 2]

View source ↗

Summary

A Phase 2 study of activated protein C for treating acute lung injury/acute respiratory distress syndrome was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Xigran (drotrecogin alfa (activated))

Snippet

Sponsor: University of California, San Francisco | Conditions: Respiratory Distress Syndrome, Adult | Phase 2 | Status: TERMINATED